Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Clinical trial NCT05806931 · RECRUITING
Trial details
- NCT number
- NCT05806931
- Sponsor
- Rutgers, The State University of New Jersey
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-17
- Primary completion
- 2026-05-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.